Effectiveness of mindfulness-based cognitive therapy in patients with anxiety disorders in secondary-care settings: A randomized controlled trial.
anxiety disorders
cognitive behavioral therapy
mindfulness
randomized controlled trial
secondary care
Journal
Psychiatry and clinical neurosciences
ISSN: 1440-1819
Titre abrégé: Psychiatry Clin Neurosci
Pays: Australia
ID NLM: 9513551
Informations de publication
Date de publication:
Feb 2020
Feb 2020
Historique:
received:
23
05
2019
revised:
01
10
2019
accepted:
30
10
2019
pubmed:
28
11
2019
medline:
15
12
2020
entrez:
28
11
2019
Statut:
ppublish
Résumé
The primary objective of this study was to examine the effectiveness of mindfulness-based cognitive therapy (MBCT) in secondary-care settings where the vast majority of the patients have already undergone pharmacotherapy but have not remitted. Eligible participants were aged between 20 and 75 years and met the criteria for panic disorder/agoraphobia or social anxiety disorder specified in the DSM-IV. They were randomly assigned to either the MBCT group (n = 20) or the wait-list control group (n = 20). The primary outcome was the difference in mean change scores between pre- and post-intervention assessments on the State-Trait Anxiety Inventory (STAI). The outcome was analyzed using an intent-to-treat approach and a mixed-effect model repeated measurement. We observed significant differences in mean change scores for the STAI State Anxiety subscale (difference, -10.1; 95% confidence interval, -16.9 to -3.2; P < 0.005) and STAI Trait Anxiety subscale (difference, -11.7; 95% confidence interval, -17.0 to -6.4; P < 0.001) between the MBCT and control groups. MBCT is effective in patients with anxiety disorders in secondary-care settings where the vast majority of patients are treatment-resistant to pharmacotherapy.
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
132-139Subventions
Organisme : The Ministry of Education, Culture, Sports, Science and Technology is the official name. Ministry of Education, Culture, Sport, Science, and Technology
ID : KAKENHI Grant Number: 25460629
Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2019 The Authors. Psychiatry and Clinical Neurosciences © 2019 Japanese Society of Psychiatry and Neurology.
Références
Keller MB. Social anxiety disorder clinical course and outcome: Review of Harvard/Brown Anxiety Research Project (HARP) findings. J. Clin. Psychiatry 2006; 67: 14-19.
Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry 2005; 62: 617-627.
Alonso J, Angermeyer MC, Bernert S et al. Prevalence of mental disorders in Europe: Results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr. Scand. Suppl. 2004; 420: 21-27.
Kawakami N, Takeshima T, Ono Y et al. Twelve-month prevalence, severity, and treatment of common mental disorders in communities in Japan: Preliminary finding from the World Mental Health Japan Survey 2002-2003. Psychiatry Clin. Neurosci. 2005; 59: 441-452.
Greenberg PE, Sisitsky T, Kessler RC et al. The economic burden of anxiety disorders in the 1990s. J. Clin. Psychiatry 1999; 60: 427-435.
McCrone P, Dhanasiri S, Patel A, Knapp M, Lawton-Smith S. Paying the Price: The Cost of Mental Health Care in England to 2026. King's Fund, London, 2008.
Sado M, Takechi S, Inagaki A et al. Cost of anxiety disorders in Japan in 2008: A prevalence-based approach. BMC Psychiatry 2013; 13: 338.
National Institute for Health and Clinical Excellence. Obsessive-compulsive disorder and body dysmorphic disorder: Treatment. NICE; 2005. (Clinical guideline [CG31]). Available from: https://www.nice.org.uk/guidance/cg31
National Institute for Health and Clinical Excellence. Generalised anxiety disorder and panic disorder in adults: Management. NICE; 2011. (Clinical guideline [CG113]). Available from: https://www.nice.org.uk/guidance/cg113
National Institute for Health and Clinical Excellence. Social anxiety disorder: Recognition, assessment and treatment. NICE; 2013. (Clinical guideline [CG159]). Available from: https://www.nice.org.uk/guidance/cg159
McHugh RK, Whitton SW, Peckham AD, Welge JA, Otto MW. Patient preference for psychological vs pharmacologic treatment of psychiatric disorders: A meta-analytic review. J. Clin. Psychiatry 2013; 74: 595-602.
Segal ZV, Williams JMG, Teasdale JD. Mindfulness-Based Cognitive Therapy for Depression: A New Approach to Preventing Relapse. Guilford Press, New York, 2012.
Kabat-Zinn J. Full Catastrophe Living: Using the Wisdom of Your Body and Mind to Face Stress, Pain, and Illness. Delacorte Press, New York, 1990.
Strauss C, Cavanagh K, Oliver A, Pettman D. Mindfulness-based interventions for people diagnosed with a current episode of an anxiety or depressive disorder: A meta-analysis of randomised controlled trials. PLoS One 2014; 9: e96110.
Kocovski NL, Fleming JE, Hawley LL, Huta V, Antony MM. Mindfulness and acceptance-based group therapy versus traditional cognitive behavioral group therapy for social anxiety disorder: A randomized controlled trial. Behav. Res. Ther. 2013; 51: 889-898.
Donald J, Abbott MJ, Smith E. Comparison of attention training and cognitive therapy in the treatment of social phobia: A preliminary investigation. Behav. Cogn. Psychother. 2014; 42: 74-91.
Sundquist J, Lilja A, Palmer K et al. Mindfulness group therapy in primary care patients with depression, anxiety and stress and adjustment disorders: Randomised controlled trial. Br. J. Psychiatry 2015; 206: 128-135.
Goldin PR, Morrison A, Jazaieri H, Brozovich F, Heimberg R, Gross JJ. Group CBT versus MBSR for social anxiety disorder: A randomized controlled trial. J. Consult. Clin. Psychol. 2016; 84: 427-437.
Koszycki D, Thake J, Mavounza C, Daoust JP, Taljaard M, Bradwejn J. Preliminary investigation of a mindfulness-based intervention for social anxiety disorder that integrates compassion meditation and mindful exposure. J. Altern. Complement. Med. 2016; 22: 363-374.
Wong SY, Yip BH, Mak WW et al. Mindfulness-based cognitive therapy v. group psychoeducation for people with generalised anxiety disorder: Randomised controlled trial. Br. J. Psychiatry 2016; 209: 68-75.
Spielberger CD, Gorsuch RL, Lushene R, Vagg PR, Jacobs GA. Manual for the State-Trait Anxiety Inventory. California Consulting Psychologists Press, 1983.
Radloff LS. The CES-D scale: A self-report depression scale for research in the general population. Appl. Psychol. Measur. 1977; 1: 385-401.
Kessler RC, Barker PR, Colpe LJ et al. Screening for serious mental illness in the general population. Arch. Gen. Psychiatry 2003; 60: 184-189.
Baer RA, Smith GT, Hopkins J, Krietemeyer J, Toney L. Using self-report assessment methods to explore facets of mindfulness. Assessment 2006; 13: 27-45.
Brooks R. EuroQol: The current state of play. Health Policy 1996; 37: 53-72.
Ware J Jr, Kosinski M, Keller SD. A 12-item short-form health survey: Construction of scales and preliminary tests of reliability and validity. Med. Care 1996; 34: 220-233.
Ware JE Jr, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36). I. Conceptual framework and item selection. Med. Care 1992; 30: 473-483.
McHorney CA, Ware JE Jr, Raczek AE. The MOS 36-item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med. Care 1993; 31: 247-263.
Rytwinski NK, Fresco DM, Heimberg RG et al. Screening for social anxiety disorder with the self-report version of the Liebowitz Social Anxiety Scale. Depress. Anxiety 2009; 26: 34-38.
Chambless DL, Caputo GC, Jasin SE, Gracely EJ, Williams C. The mobility inventory for agoraphobia. Behav. Res. Ther. 1985; 23: 35-44.
Kim YW, Lee SH, Choi TK et al. Effectiveness of mindfulness-based cognitive therapy as an adjuvant to pharmacotherapy in patients with panic disorder or generalized anxiety disorder. Depress. Anxiety 2009; 26: 601-606.
Bandelow B, Zohar J, Hollander E et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision. World J. Biol. Psychiatry 2008; 9: 248-312.
Chambless DL, Sharpless BA, Rodriguez D et al. Psychometric properties of the Mobility Inventory for Agoraphobia: Convergent, discriminant, and criterion-related validity. Behav. Ther. 2011; 42: 689-699.
Herdman M, Gudex C, Lloyd A et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual. Life Res. 2011; 20: 1727-1736.
Cunningham JA, Kypri K, McCambridge J. Exploratory randomized controlled trial evaluating the impact of a waiting list control design. BMC Med. Res. Methodol. 2013; 13: 150.
Rush AJ, Carmody TJ, Ibrahim HM et al. Comparison of self-report and clinician ratings on two inventories of depressive symptomatology. Psychiatr. Serv. 2006; 57: 829-837.
Dunlop BW, Li T, Kornstein SG et al. Correlation between patient and clinician assessments of depression severity in the PREVENT study. Psychiatry Res. 2010; 177: 177-183.